Novel Molecular Interceptive and Therapeutic Targets and Noninvasive Prognostic and Predictive Biomarkers in Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 86
Special Issue Editor
Interests: prostate and breast cancers; molecular mechanisms of cancer progression; pre-clinical mouse models; targeted therapies; natural anticancer agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce the call for submissions to a Special Issue of Cancers focused on the topic of novel molecular interceptive and therapeutic targets, and noninvasive prognostic and predictive biomarkers in prostate cancer. Prostate cancer continues to be a significant health concern worldwide, and there is a crucial need to explore innovative approaches for its interception and treatment.
This Special Issue aims to provide a comprehensive overview of the current advancements in the field of prostate cancer research, with a particular focus on novel molecular targets for detecting cancer at its very early stage or achieving partial or complete remission in advanced cancer. We invite the submission of original research articles and reviews that address prostate cancer genomic and epigenomic heterogeneity and alterations during its stage-defined progression.
The following various aspects of prostate cancer, including but not limited to, are of interest:
- Modeling different stages of prostate cancer in genetically engineered mouse models;
- Identification and characterization of novel molecular targets in prostate cancer;
- Development and evaluation of targeted therapies for prostate cancer (pre-clinical and clinical studies);
- Noninvasive prognostic and predictive biomarkers for risk assessment and treatment response evaluation, including promising urinary non-coding RNAs (miRNAs);
- Innovative approaches for personalized medicine and precision oncology in prostate cancer.
All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians and experts in the field of prostate cancer research and oncology.
By consolidating the latest research findings and clinical experiences, we aim to advance our understanding of molecular determinants of different stages of prostate cancer and facilitate the development of effective intervention strategies. Your valuable contributions to this Special Issue will significantly contribute to the progress in this field.
Should you have any questions, require further information or need any assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue.
We enthusiastically anticipate your valuable submissions.
Prof. Dr. Anait S. Levenson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- molecular targets
- tumor heterogeneity
- targeted interception and therapies
- noninvasive biomarkers
- precision oncology
